Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $6.2 million.

  • Relay Therapeutics' Non Operating Income fell 2446.76% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.5 million, marking a year-over-year decrease of 1447.83%. This contributed to the annual value of $34.8 million for FY2024, which is 1203.15% up from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Non Operating Income is $6.2 million, which was down 2446.76% from $6.5 million recorded in Q2 2025.
  • Relay Therapeutics' 5-year Non Operating Income high stood at $9.0 million for Q1 2024, and its period low was $157000.0 during Q3 2021.
  • In the last 5 years, Relay Therapeutics' Non Operating Income had a median value of $6.5 million in 2025 and averaged $5.0 million.
  • In the last 5 years, Relay Therapeutics' Non Operating Income tumbled by 8180.9% in 2021 and then skyrocketed by 190299.63% in 2022.
  • Over the past 5 years, Relay Therapeutics' Non Operating Income (Quarter) stood at $267000.0 in 2021, then skyrocketed by 1903.0% to $5.3 million in 2022, then soared by 62.7% to $8.7 million in 2023, then rose by 3.15% to $9.0 million in 2024, then tumbled by 30.45% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $6.5 million for Q2 2025, and $7.8 million during Q1 2025.